Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2014-04-30
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will be classified into 4 groups based on Atopic Dermatitis (AD)/Non-Atopic (NA) status and Staphylococcus aureus (S. aureus) colonization (negative or positive):
* AD S. aureus negative
* AD S. aureus positive
* NA S. aureus negative and
* NA S. aureus positive.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Registry for the Atopic Dermatitis Research Network
NCT01494142
Identification of Epidermal Signatures in Patients With Atopic Dermatitis
NCT02680405
The Role of Bacterial Toxins in Human Skin Disease
NCT02910791
Immune Reactions in Contact Dermatitis Affected Skin
NCT01546298
Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers
NCT03625219
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will compare the skin barrier and immune response of people with and without atopic dermatitis in relation to whether Staph bacteria is growing on their skin.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ADStaph-
Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
No interventions assigned to this group
ADStaph+
Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
No interventions assigned to this group
NAStaph-
Non-atopic healthy participants without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group
No interventions assigned to this group
NAStaph+
Non-atopic healthy participants with S. aureus skin colonization. As the NAStaph+ phenotype is expected to be rare, as many participants as possible will be enrolled in this group; however, we do not expect to enroll 45 participants in this group.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-Hispanic Caucasian males and females 18 to 60 years of age, inclusive, at the time of Enrollment
* Who are enrolled in the ADRN Registry study
* Who have active AD (lesions present) with or without a history of Eczema Herpeticum (EH) as defined in the ADRN Standard Diagnostic Criteria OR who meet criteria for the NA diagnostic group as defined in the ADRN Standard Diagnostic Criteria
* Who are willing to sign the informed consent form prior to initiation of any study procedures.
Exclusion Criteria
* Who are pregnant
* Who have an active systemic malignancy. Uncomplicated non-melanoma skin cancer and melanoma in situ with documentation of complete excision are not exclusionary
* Who have any skin disease other than AD that might compromise the SC barrier (e.g., bullous disease, psoriasis, cutaneous T cell lymphoma \[also called Mycosis Fungoides or Sezary syndrome\], dermatitis herpetiformis, Hailey-Hailey, or Darier's disease)
* Who have a history of systemic immunological illness (e.g., human immunodeficiency virus \[HIV\] or systemic lupus erythematosus \[SLE\]) other than the condition being studied
* Who have active EH or eczema vaccinatum (EV)
* Who have a history of serious or life-threatening reaction to latex, tape, or adhesives
* Who are determined to be not eligible based on the opinion of the Investigator.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Atopic Dermatitis Research Network
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lisa Beck, MD
Role: STUDY_CHAIR
University of Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Jewish Health
Denver, Colorado, United States
University of Rochester
Rochester, New York, United States
Oregon Health & Science University
Portland, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
National Institute of Allergy and Infectious Diseases (NIAID)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAIT ADRN-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.